Bipolar Depression Market is expected to grow with a CAGR of 16.69% during the study period [2017-30] in 7MM, reports DelveInsight

Bipolar Depression Market is expected to grow with a CAGR of 16.69% during the study period [2017-30] in 7MM, reports DelveInsight

PR Newswire

LAS VEGAS, Dec. 14, 2020

LAS VEGAS, Dec. 14, 2020 /PRNewswire/ -- The Bipolar Depression market report by DelveInsight analyses that the market will experience a boost due to the increase in the patient pool and launch of the emerging therapies such as Abilify, Lumateperone/ITI-007, NRX-100/NRX-101, Zuranolone, SEP-4199, and Falkieri during the forecast period.


The Bipolar Depression Market Analysis report offers insights on disease comprehension, historical and forecasted epidemiology; and Bipolar Depression market trends in the 7MM (United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). The research report also covers the current Bipolar Depression treatment practice/algorithm, market drivers, market barriers and unmet medical needs to evaluate the underlying potential of the Bipolar Depression market. 

Key Takeaways of Bipolar Depression Report 

Have a query regarding how the trends will be influencing the Bipolar Depression market, talk to our analysts @ 

Bipolar Disorder, formerly known as Manic Depressive Illness or Manic Depression, is a mental disorder that is characterized by wide mood swings from high (manic) to low (depressed). In Bipolar Depression, the patient might feel sad, indifferent, or hopeless, in combination with a very low activity level. Bipolar Disorder is divided mainly into four subtypes Bipolar Disorder-I, Bipolar Disorder-II, Cyclothymic Disorder, and Bipolar Disorder not otherwise specified (NOS). The classification is based on the characteristics of mood swings. Depression is majorly seen in Bipolar Disorder-I type and Bipolar Disorder-II type.  Bipolar Depression Symptoms include feeling sad or anxious; restless; concentration issues; trouble falling asleep, waking up too soon, or sleeping too much; uninterested; experiencing hopeless or worthless, or contemplating about death; unable to do even simple things, and talking very slowly, feeling like one has nothing to say, or forgetting a lot. There is no test available for the Bipolar Disorder diagnosis; a psychiatrist can diagnose it based on the patient's history and symptoms. 

As per DelveInsight's analysts, the total Bipolar Depression diagnosed prevalent population in the 7MM was 1,857,545 in 2017. The estimates show that the highest diagnosed Bipolar Depression Prevalence in the United States was 740,715 cases in the same year.  Also, it was observed that the number of patients experiencing depressive episodes is higher in BD-II than BD-I in the 7MM. 

The report provides a comprehensive historical and forecasted analysis of Bipolar Depression Epidemiology segmented as: 

Bipolar Depression Market 

Bipolar Disorder is a highly recurrent disorder, and sometimes medication required to continue even if the patient feels well. The treatment has two phases:- the acute phase and the maintenance phase. Acute-phase treatment is aimed at the management of acute mood episodes (manic, hypomanic, or depressive). Maintenance-phase treatment is intended for preventing recurrences of acute episodes. Each phase is associated with particular treatment requirements, and available pharmacotherapies have shown differential effects as per the illness phase. Most commonly, mood stabilizers, antipsychotics, antidepressants, anti anxiety medications, and psychotherapy are used.

The US FDA, in October 2008, had allowed once-daily Seroquel XR (quetiapine fumarate) Extended-Release Tablets for the acute treatment of the depressive episodes associated with bipolar disorder, the manic and mixed episodes associated with bipolar I disorder, and the maintenance treatment of bipolar I disorder as adjunctive therapy to lithium or divalproex. Seroquel XR is the only medication in its class authorized by the FDA for treatment of both major depressive disorder as adjunctive therapy and acute depressive episodes associated with bipolar disorder as monotherapy. The drug has been allowed for adults. Seroquel XR and Seroquel are also approved in the EU to prevent recurrence of bipolar disorder in patients whose manic, mixed or depressive episode has reacted to quetiapine treatment.

Oral Zyprexa and fluoxetine in combination is used for the treatment of depressive episodes associated with bipolar I disorder, but Zyprexa monotherapy is not indicated for the same. 

The US FDA had given nod to lurasidone (Latuda, Sunovion Pharmaceuticals Inc) for the treatment of major depressive episodes associated with bipolar I disorder (bipolar depression) in children and adolescents aged 10–17 years. Latuda was given the approval to improve depressive symptoms in patients with bipolar disorder in Japan in March 2020. 

The US FDA permitted a supplemental New Drug Application for Vraylar for the expanded treatment of depressive episodes associated with bipolar I disorder in adults in May 2019. Hungary-based Gedeon Richter Ltd. developed Vraylar (cariprazine) and licensed to Allergan; has also been sanctioned in the US for treatment of manic or mixed episodes associated with bipolar I disorder in adults. 

Visit here to get access to the complete Bipolar Depression Market report 

Although, the expected entry of emerging therapies such as Abilify (Aripiprazole), NRX-100/NRX101, among others is expected to boost the Bipolar Depression market in the forecasted period (2020–2030),though the launch of generics such as of Seroquel, Zyprexa and Latuda, the BPD market is going to experience a dip in its growing size. Strict pricing and reimbursement policies can also become an obstacle in the market growth. Besides, commercial and regulatory challenges, clinical challenges such as fewer randomized controlled trials (RCTs) of acute Bipolar Depression is also a major barrier that delays the clinical investigation of novel therapeutic targets. However, to cope up with the challenges posed, large-scale collaborative studies are underway that are applying new methods and are also anticipated to provide novel insights into disease mechanisms with the potential for the development of more targeted therapeutics. 

Furthermore, increasing Bipolar Depression prevalence along with an increase in the awareness regarding mental disorders and rise in the popularity as well as the demand of new technologies such as IoT devices are expected to improve medication adherence thereby adding significantly to the Bipolar Depression market size growth in the forecast period 2020-30.

Scope of the Report

Table of Contents

1.  Key Insights

2.  Executive Summary of Bipolar Depression

3.  Bipolar Depression Market Overview at a Glance

4.  Bipolar Depression Disease Background and Overview

5.  Case Reports  

6.  Bipolar Depression Epidemiology and Patient Population   

7.  United States Bipolar Depression Epidemiology

8.  EU5 Bipolar Depression Epidemiology

8.1.  Germany Epidemiology

8.2.  France Epidemiology

8.3.  Italy Epidemiology

8.4.  Spain Epidemiology

8.5.  United Kingdom Epidemiology

9.  Japan Bipolar Depression Epidemiology

10.  Bipolar Depression Current Treatment and Medical Practices

11.  Unmet Needs

12.  Bipolar Depression Marketed Products

12.1. Vraylar (Cariprazine): Allergan (AbbVie)/Gedeon Richter

12.2. Latuda (Lurasidone Hydrochloride): Sunovion Pharmaceuticals (Sumitomo Dainippon Pharma)

13.  Bipolar Depression Emerging Therapies

13.1. Key Cross Competition

13.2. Abilify (Aripiprazole): Otsuka Pharmaceutical

13.3. Lumateperone/ITI-007: Intra-cellular Therapies

13.4. NRX-100/NRX-101: NeuroRx

13.5. Psilocybin: COMPASS Pathways

13.6. Zuranolone (SAGE-217): Sage Therapeutics

13.7. SEP-4199: Sunovion/Sumitomo Dainippon Pharma

13.8. ILT101: Iltoo Pharma

13.9. Falkieri (Esketamine DPI): Celon Pharma

14.  Bipolar Depression 7MM Market Analysis

15.  United States Bipolar Depression Market Outlook

16.  EU-5 countries Bipolar Depression Market Outlook

16.1.  Germany Market Size

16.2.  France Market Size

16.3.  Italy Market Size

16.4.  Spain Market Size

16.5.  United Kingdom Market Size

17.  Japan Bipolar Depression Market Outlook

17.1.  Japan Market Size

18.  Bipolar Depression Market Drivers

19.  Bipolar Depression Market Barriers

20.  SWOT Analysis

21.  Reimbursement and Bipolar Depression Market Access

22.  Appendix

23.  DelveInsight Capabilities

24.  Disclaimer

25.  About DelveInsight

Browse Detailed TOC, Tables, Figures, Emerging Drugs and Companies @ 

Related Reports


DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
Shruti Thakur



Voltar noticias em Inglês